These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36454570)

  • 1. Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States.
    Chokkalingam AP; Hayden J; Goldman JD; Li H; Asubonteng J; Mozaffari E; Bush C; Wang JR; Kong A; Osinusi AO; Gottlieb RL
    JAMA Netw Open; 2022 Dec; 5(12):e2244505. PubMed ID: 36454570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
    Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
    JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
    Garibaldi BT; Wang K; Robinson ML; Zeger SL; Bandeen-Roche K; Wang MC; Alexander GC; Gupta A; Bollinger R; Xu Y
    JAMA Netw Open; 2021 Mar; 4(3):e213071. PubMed ID: 33760094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness Study.
    Garibaldi BT; Wang K; Robinson ML; Betz J; Caleb Alexander G; Andersen KM; Joseph CS; Mehta HB; Korwek K; Sands KE; Fisher AM; Bollinger RC; Xu Y
    Clin Infect Dis; 2022 Aug; 75(1):e516-e524. PubMed ID: 34910128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing patterns and clinical outcomes of hospitalized patients with COVID-19 severe pneumonia treated with remdesivir according to vaccination status: results from a real-world retrospective study.
    Mengato D; Mazzitelli M; Francavilla A; Bettio M; Sasset L; Presa N; Pivato L; Lo Menzo S; Trevenzoli M; Venturini F; Gregori D; Cattelan AM
    Clin Exp Med; 2023 Oct; 23(6):2749-2756. PubMed ID: 36961678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis.
    Veronese N; Di Gennaro F; Frallonardo L; Ciriminna S; Papagni R; Carruba L; Agnello D; De Iaco G; De Gennaro N; Di Franco G; Naro L; Brindicci G; Rizzo A; Bavaro DF; Garlisi MC; Santoro CR; Signorile F; Balena F; Mansueto P; Milano E; Giannitrapani L; Fiordelisi D; Mariani MF; Procopio A; Lattanzio R; Licata A; Vernuccio L; Amodeo S; Guido G; Segala FV; Barbagallo M; Saracino A
    Sci Rep; 2024 Apr; 14(1):9303. PubMed ID: 38654033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.
    Gressens SB; Esnault V; De Castro N; Sellier P; Sene D; Chantelot L; Hervier B; Delaugerre C; Chevret S; Molina JM;
    PLoS One; 2022; 17(2):e0262564. PubMed ID: 35176057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
    Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
    JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice.
    Mozaffari E; Chandak A; Gottlieb RL; Chima-Melton C; Read SH; Jiang H; Chiang M; Lee E; Gupta R; Berry M; Kalil AC
    Clin Infect Dis; 2023 Dec; 77(12):1626-1634. PubMed ID: 37556727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5.
    Molina KC; Webb BJ; Kennerley V; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Aggarwal NR; Ginde AA
    BMC Infect Dis; 2024 Aug; 24(1):802. PubMed ID: 39118052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score.
    Sellers J; Chang J; Jones J; Hintze TD
    Pulm Pharmacol Ther; 2023 Feb; 78():102188. PubMed ID: 36603741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Propensity Score-Matched Observational Study of Remdesivir in Patients with COVID-19 and Severe Kidney Disease.
    Seethapathy R; Zhao S; Long JD; Strohbehn IA; Sise ME
    Kidney360; 2022 Feb; 3(2):269-278. PubMed ID: 35373125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
    Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
    J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Treatment with Remdesivir and 30-day Hospital Readmissions in Patients Hospitalized with COVID-19.
    Finn A; Jindal A; Andrea SB; Selvaraj V; Dapaah-Afriyie K
    Am J Med Sci; 2022 May; 363(5):403-410. PubMed ID: 35151637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of early remdesivir administration in COVID-19 disease progression in hospitalised patients.
    Platzer M; Totschnig D; Karolyi M; Clodi-Seitz T; Wenisch C; Zoufaly A
    Wien Klin Wochenschr; 2024 Aug; 136(15-16):458-464. PubMed ID: 38884783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort.
    Mozaffari E; Chandak A; Zhang Z; Liang S; Thrun M; Gottlieb RL; Kuritzkes DR; Sax PE; Wohl DA; Casciano R; Hodgkins P; Haubrich R
    Clin Infect Dis; 2022 Aug; 75(1):e450-e458. PubMed ID: 34596223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study.
    Hussain Alsayed HA; Saheb Sharif-Askari F; Saheb Sharif-Askari N; Hussain AAS; Hamid Q; Halwani R
    PLoS One; 2021; 16(10):e0258643. PubMed ID: 34699552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
    Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
    Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.